10-Q: Moderna Reports Q1 2025 Results: Revenue Declines Amid Transition to Seasonal Vaccine Market

Moderna's Q1 2025 revenue decreased due to lower COVID vaccine sales, reflecting the shift to a seasonal respiratory vaccine market, while the company progresses its pipeline and manages costs.

Summary

• Moderna's Q1 2025 net product sales were $86 million, down from $167 million in Q1 2024.
• The decrease is primarily due to lower COVID vaccine sales, reflecting the transition to a seasonal respiratory vaccine market.
• Loss per share was $(2.52) for Q1 2025, compared to $(3.07) for Q1 2024.
• Research and development expenses decreased by $207 million, or 19%, compared to Q1 2024.
• Selling, general, and administrative expenses decreased by $62 million, or 23%, compared to Q1 2024.
• The company is progressing its pipeline, with regulatory submissions for next-generation COVID and RSV vaccines.
• Moderna expects demand for its COVID and RSV vaccines to follow a seasonal pattern.
• The company anticipates a decline in net product sales for the full year 2025 compared to 2024.
• Moderna believes its cash, cash equivalents, and investments will be sufficient to fund operations and capital expenditures for at least the next 12 months.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue declined and a net loss was reported, the company is managing costs, progressing its pipeline, and has sufficient cash to fund operations for the next 12 months. The company is facing challenges but is taking steps to address them.

Positives

• Loss per share improved from $(3.07) in Q1 2024 to $(2.52) in Q1 2025.
• Research and development expenses decreased by $207 million, indicating improved cost management.
• Selling, general and administrative expenses decreased by $62 million, reflecting streamlined operations.
• Regulatory submissions are progressing for next-generation COVID and RSV vaccines.
• The company has a strong cash position to fund operations for at least the next 12 months.
• Positive Phase 3 data was shared for the RSV vaccine in high-risk adults aged 18 to 59.
• The FDA clinical hold on the Norovirus vaccine has been lifted.

Negatives

• Net product sales decreased from $167 million in Q1 2024 to $86 million in Q1 2025.
• The company experienced a net loss of $971 million in Q1 2025.
• Cost of sales as a percentage of net product sales increased to 104% in Q1 2025, compared to 58% in Q1 2024.
• The Data Safety Monitoring Board (DSMB) informed Moderna that the criterion for early efficacy was not met for the CMV vaccine candidate (mRNA-1647).
• Development of the preclinical PKU candidate (mRNA-3210) has been discontinued.

Risks

• The company faces increased competition in the COVID vaccine market.
• Demand for COVID vaccines is expected to decline in 2025.
• Uncertainty around demand and increased market competition could lead to variability in cost of sales.
• The company is subject to risks related to the development and commercialization of novel medicines.
• The company is involved in patent litigation with Pfizer/BioNTech, Arbutus, and GSK.
• The company may experience unforeseen expenses, difficulties, complications, delays, and other unknown factors, which may adversely affect its business.

Future Outlook

Moderna expects demand for its COVID and RSV vaccines to follow a seasonal pattern, with higher sales during the fall and winter. The company anticipates a decline in net product sales for the full year 2025 compared to 2024, primarily due to lower expected vaccination rates and increased competition. Moderna believes its cash, cash equivalents, and investments will be sufficient to fund operations and capital expenditures for at least the next 12 months.

Management Comments

• The report does not contain any direct quotes from management.

Industry Context

The report reflects the broader industry trend of transitioning from pandemic-level demand for COVID vaccines to a more seasonal and commercial market. Moderna is adapting to this shift by focusing on cost management, advancing its pipeline, and expanding its commercial infrastructure. The company's success will depend on its ability to effectively compete in the evolving vaccine market and successfully launch new products.

Comparison to Industry Standards

• It is difficult to compare Moderna's results directly to industry standards without specific competitor data for Q1 2025.
• However, the decline in COVID vaccine sales is consistent with the broader trend of reduced demand across the industry as the pandemic transitions to an endemic phase.
• Companies like Pfizer and BioNTech, which also have COVID vaccines, are likely experiencing similar trends.
• Moderna's focus on developing combination vaccines (e.g., flu+COVID) aligns with industry efforts to improve vaccine convenience and uptake.
• The company's investment in mRNA technology and its diverse pipeline position it to compete in various vaccine and therapeutic markets.

Legal Proceedings

• Moderna is involved in patent litigation with Pfizer/BioNTech, Arbutus, and GSK.
• The U.S. litigation with Pfizer/BioNTech has been stayed pending the outcome of IPRs.
• The Dusseldorf Regional Court in Germany ruled that Pfizer and BioNTech violated one of Moderna's European patents.
• Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) filed five international lawsuits asserting that Moderna's manufacture and sale of Spikevax and/or mRESVIA infringes certain patents concerning lipid nanoparticles.
• GlaxoSmithKline Biologicals SA (GSK) has filed two complaints against Moderna in the U.S. District Court for the District of Delaware, asserting that either Spikevax or mRESVIA infringe certain patents owned by GSK.

Stakeholder Impact

• Shareholders: The decline in revenue and net loss may negatively impact shareholder value.
• Employees: Cost management initiatives could lead to workforce reductions or restructuring.
• Customers: The company's ability to successfully launch new products will impact the availability of innovative vaccines and therapeutics.
• Suppliers: Changes in demand for COVID vaccines could affect supply agreements and purchase commitments.
• Creditors: The company's strong cash position provides assurance of its ability to meet its financial obligations.

Next Steps

• Continue regulatory submissions for next-generation COVID and RSV vaccines.
• Await FDA decisions on mRNA-1283 and mRNA-1345.
• Conduct interim data readout for the seasonal flu vaccine (mRNA-1010) in summer 2025.
• Continue Phase 3 clinical trials for INT, CMV, and Norovirus vaccines.
• Start a registrational study for MMA therapeutic in 2025.

Key Dates

Keywords

mRNA, Vaccines, COVID-19, RSV, Clinical Trials, Regulatory Approval, Financial Results, Product Sales, Research and Development, Moderna